CTLA4-Ig protects tacrolimus-induced oxidative stress via inhibiting the AKT/FOXO3 signaling pathway in rats

• Published in: The Korean journal of internal medicine 2023, 38(3), , pp.393-405
• Main Authors: Jin, Long, Shen, Nan, Wen, Xinyu, Wang, Weidong, Lim, Sun Woo, Yang, Chul Woo
• Format: Article
• Language: English
• Subjects: Abatacept - metabolism; Abatacept - pharmacology; akt/foxo3 signaling pathway; Animals; Apoptosis; Apoptosis Regulatory Proteins - metabolism; CTLA-4 Antigen; ctla4-ig; Forkhead Box Protein O3 - metabolism; Humans; Insulin-Like Growth Factor I - metabolism; Insulin-Like Growth Factor I - pharmacology; Original; Oxidative Stress; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; renal injury; Renal Insufficiency; Signal Transduction; tacrolimus; Tacrolimus - pharmacology; 내과학
• ISSN: 1226-3303; 2005-6648
• DOI: 10.3904/kjim.2022.293

Although the conversion from tacrolimus (TAC) to cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin (CTLA4-Ig) is effective in reducing TAC-induced nephrotoxicity, it remains unclear whether CTLA4-Ig has a direct effect on TAC-induced renal injury. In this study, we evaluated the effects of CTLA4-Ig on TAC-induced renal injury in terms of oxidative stress. In vitro study was performed to assess the effect of CTLA4-Ig on TAC-induced cell death, reactive oxygen species (ROS), apoptosis, and the protein kinase B (AKT)/forkhead transcription factor (FOXO) 3 pathway in human kidney 2 cells. In the in vivo study, the effect of CTLA4-Ig on TAC-induced renal injury was evaluated using renal function, histopathology, markers of oxidative stress (8-hydroxy-2'-deoxyguanosine) and metabolites (4-hydroxy-2-hexenal, catalase, glutathione S-transferase, and glutathione reductase), and activation of the AKT/FOXO3 pathway with insulin-like growth factor 1 (IGF-1). CTLA4-Ig significantly decreased cell death, ROS, and apoptosis caused by TAC. TAC treatment increased apoptotic cell death and apoptosis-related proteins (increased Bcl-2-associated X protein and caspase-3 and decreased Bcl-2), but it was reversed by CTLA4-Ig treatment. The activation of p-AKT and p-FOXO3 by TAC decreased with CTLA4-Ig treatment. TAC-induced renal dysfunction and oxidative marker levels were significantly improved by CTLA4-Ig in vivo. Concomitant IGF-1 treatment abolished the effects of CTLA4-Ig. CTLA4-Ig has a direct protective effect on TAC-induced renal injury via the inhibition of AKT/FOXO3 pathway.